The earnings call presented a strong performance with significant growth in several key segments, and strategic partnerships and product launches augmenting future prospects. However, some segments underperformed due to specific challenges, which the company is addressing. Despite these issues, Abbott maintained its full-year guidance and showed confidence in strong upcoming quarters.

Company Guidance

During Abbott's Q3 2024 earnings call, the company reported an impressive organic sales growth of over 8%, excluding COVID testing sales, and an adjusted earnings per share of $1.21. Notable achievements included a 3.5% increase in Nutrition sales, driven by double-digit growth in U.S. Pediatric Nutrition (12%) and U.S. Adult Nutrition (11.5%). Core Laboratory Diagnostics saw a 4.5% increase when excluding COVID testing sales. The Established Pharmaceuticals Division experienced a 7% sales increase, with robust growth across Latin America, Southeast Asia, and the Middle East. The Med Tech portfolio showed remarkable strength, with sales growing over 13%, highlighted by a 21% increase in Diabetes Care sales, where continuous glucose monitors exceeded $1.6 billion. Electrophysiology sales rose by 14%, and Structural Heart sales grew by more than 16%. Abbott's guidance for Q4 included an adjusted earnings per share forecast of $1.31 to $1.37, with an expected minimal exchange impact on reported sales.

Strong Organic Sales Growth

Abbott reported organic sales growth of more than 8%, excluding COVID testing sales, and adjusted earnings per share of $1.21.

Successful Launches and Partnerships

The company entered new strategic partnerships, launched new products, and made advancements in the R&D pipeline, including the U.S. launch of Lingo, a new glucose monitoring sensor, and a partnership with Medtronic.

Med Tech Growth

The Med Tech portfolio saw sales growth of more than 13%, driven by diabetes care, electrophysiology, and structural heart products.

Diabetes Care Segment Growth

Sales of continuous glucose monitors exceeded $1.6 billion in the quarter, growing 21%.

Electrophysiology Growth

Electrophysiology saw a 14% growth, driven by double-digit growth in the U.S. and international markets.

Structural Heart Segment Growth

The structural heart segment experienced growth of more than 16%, led by adoption of TriClip and market share capture in TAVR.

---

Abbott Laboratories (ABT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 22, 2025	2024 (Q4)	1.34 / -	1.19	―	―	―
Oct 16, 2024	2024 (Q3)	1.20 / 1.21	1.14	6.14% (+0.07)
Jul 18, 2024	2024 (Q2)	1.10 / 1.14	1.08	5.56% (+0.06)
Apr 17, 2024	2024 (Q1)	0.95 / 0.98	1.03	-4.85% (-0.05)
Jan 24, 2024	2023 (Q4)	1.19 / 1.19	1.03	15.53% (+0.16)
Oct 18, 2023	2023 (Q3)	1.10 / 1.14	1.15	-0.87% (-0.01)
Jul 20, 2023	2023 (Q2)	1.05 / 1.08	1.43	-24.48% (-0.35)
Apr 19, 2023	2023 (Q1)	0.99 / 1.03	1.73	-40.46% (-0.70)
Jan 25, 2023	2022 (Q4)	0.93 / 1.03	1.32	-21.97% (-0.29)
Oct 19, 2022	2022 (Q3)	0.94 / 1.15	1.4	-17.86% (-0.25)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ABT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 16, 2024	$116.05	$117.82	+1.53%
Jul 18, 2024	$104.19	$99.60	-4.41%
Apr 17, 2024	$108.12	$104.85	-3.02%
Jan 24, 2024	$112.31	$109.13	-2.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---